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Abstract
Background: FoxE1 is a thyroid-specific forkhead transcription factor essential for thyroid gland development, as well as for
the maintenance of the thyroid differentiated state in adults. FoxE1 recognizes and binds to a short DNA sequence present
in thyroglobulin (Tg) and thyroperoxidase (Tpo) promoters, but FoxE1 binding to regulatory regions other than Tg and Tpo
promoters remains almost unexplored. Improving knowledge of the regulatory functions of FoxE1 is necessary to clarify its
role in endocrine syndromes and cancer susceptibility.
Methodology/Principal Finding: In order to further investigate downstream FoxE1 targets, we performed a genome-wide
expression screening after knocking-down FoxE1 and obtained new insights into FoxE1 transcriptional networks in thyroid
follicular cells. After validation, we confirmed Adamts9, Cdh1, Duox2 and S100a4 as upregulated genes and Casp4, Creld2,
Dusp5, Etv5, Hsp5a, Nr4a2 and Tm4sf1 as downregulated genes when FoxE1 was silenced. In promoter regions of putative
FoxE1-regulated genes and also in the promoters of the classical thyroid genes Nis, Pax8 and Titf1, we performed an in silico
search of the FoxE1 binding motif that was in close proximity to the NF1/CTF binding sequence, as previously described for
other forkhead factors. Using chromatin immunoprecipitation we detected specific in vivo FoxE1 binding to novel
regulatory regions in two relevant thyroid genes, Nis and Duox2. Moreover, we demonstrated simultaneous binding of
FoxE1 and NF1/CTF to the Nis upstream enhancer region, as well as a clear functional activation of the Nis promoter by both
transcription factors.
Conclusions/Significance: In search for potential downstream mediators of FoxE1 function in thyroid cells, we identified
two novel direct FoxE1 target genes. To our knowledge, this is the first evidence regarding the implication of Nis and Duox2
in executing the transcriptional program triggered by FoxE1. Furthermore, this study points out the important role of FoxE1
in the regulation of a large number of genes in thyroid cells.
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Introduction
Coordinated expression of thyroid transcription factors Pax8,
FoxE1/Ttf2 and Ttf1/Nkx2-1 is essential for maintaining the
differentiated thyroid function, which involves synthesis and
secretion of thyroid hormones. These factors are encoded by
genes with paired box, forkhead box and homeobox domains,
respectively. Thyroid hormones are iodinated, and therefore
thyroid cells actively concentrate iodide through a sodium
dependent co-transporter, Nis, a glycoprotein located in the basal
membrane. The iodide is transported to the apical membrane,
where thyroperoxidase (Tpo) iodinates the tyrosine residues of the
main thyroid protein thyroglobulin (Tg) that serves as a storage for
thyroid hormones [1,2].
FoxE1, formerly known as thyroid transcription factor 2 or
Ttf2, is a thyroid-specific transcription factor that belongs to the
forkhead/winged-helix family [3]. Fox proteins are a superfamily
of evolutionarily conserved transcriptional regulators, which share
a highly conserved forkhead box or winged helix DNA binding
domain. Forkhead factors control a wide range of biological
processes, and some of them are key regulators of embryogenesis
and play important roles in cell differentiation and development,
hormone responsiveness and aging [4,5].
FoxE1, as a member of the Fox family, is able to interact with
nucleosomes through its winged-helix DNA binding domain and
to alter chromatin structure, creating a locally exposed domain
necessary for the action of other transcription factors [6]. This
intrinsic property defines FoxE1 as a pioneer transcription factor
[7], essential during thyroid development and differentiation, as
well as for the maintenance of the thyroid differentiated state in
adults [2].
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Foxe1-null mice exhibit an ectopic (50%) or completely absent
(50%) thyroid gland and severe cleft palate. Consequently, FoxE1
seems to be crucial either for the migration of the thyroid cell
precursors or for repressing differentiation until migration has
completed [8].
Human FOXE1 mutations cause the Bamforth–Lazarus syn-
drome (OMIM 241850), which is associated with congenital
hypothyroidism, cleft palate and spiky hair, with or without
choanal atresia, bifid epiglottis and ocular hypertelorism [9,10].
Moreover, FOXE1 variations have been associated with suscepti-
bility to several types of cancer [11,12,13], including papillary
thyroid cancer [14,15,16].
FoxE1 was initially identified as a nuclear protein [3] that
recognizes and binds to DNA sequences present in the promoters
of two thyroid-specific genes: thyroglobulin (Tg) [17] and
thyroperoxidase (Tpo) [18]. FoxE1 usually promotes transcrip-
tional activation of the Tg and Tpo genes; however, it can also act
as a promoter-specific transcriptional repressor of both genes [19].
Putative FoxE1-binding sites previously identified in the Tg and
Tpo promoters share the core sequence AAACA [20]. Moreover,
in the Tpo promoter FoxE1 forms part of an interaction-complex
together with the transcription factor NF1/CTF, whose final result
is to turn on the expression of the Tpo gene in response to external
hormonal stimuli [21].
Nevertheless, FoxE1 binding to DNA sequences other than the
Tg and Tpo promoters remains almost unexplored. Only two
studies have reported other FoxE1 targets, but both were
conducted in heterologous expression systems [22,23].
In order to further investigate FoxE1 downstream targets in
thyroid epithelial cells, we performed a genome-wide screening
using expression arrays in FoxE1 knock-down cells followed by a
search of direct target genes containing in their promoters both
FoxE1 and NF1/CTF binding sites. The results obtained in this
study provide new insights into FoxE1 transcriptional networks in
differentiated thyroid cells and predict involvement of FoxE1 in
relevant biological processes and pathways. These data may lead
to a better understanding of thyroid biology.
Materials and Methods
Cell Culture
PCCl3 cells, a continuous line of rat thyroid follicular cells [24],
were cultured in Coon’s modified Ham’s F-12 medium supple-
mented with 5% donor calf serum and a six-hormone mixture
[25]. These cells express thyroid-specific genes (Tg, Tpo, and Nis) as
well as thyroid-specific transcription factors (Ttf1, FoxE1, and
Pax8) [26] and therefore constitute a good model system to study
differentiation and growth regulation in a thyroid epithelial cell
setting.
HeLa cells were grown in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 5% fetal bovine serum.
RNA Interference
PCCl3 cells were transfected with 25 nM of FoxE1 siRNA (Rat
FoxE1 ON-TARGETplus SMARTpool) or with scrambled
siRNA (ON-TARGETplus Non-targeting Pool) using Dharma-
FECT 1 Transfection Reagent and following the manufacturer’s
protocol (Dharmacon, Denver, USA).
In order to establish optimal conditions for FoxE1 silencing,
duplicate samples were harvested at different time points (24, 48
and 72 h) after transfection, and total protein was extracted. FoxE1
silencing was tested by western blotting using a polyclonal FoxE1
antibody (Biopat, Milan, Italy) (data not shown). Once 48 hours
was defined as the best time point for FoxE1 silencing, we
performed additional transfections, four biological replicates for
each condition, to isolate total protein and total RNA using
TRIzol reagent (Invitrogen, Carlsbad, CA) following the manu-
facturer’s recommended protocol.
Expression Arrays
FoxE1-dependent gene expression was tested using expression
arrays (Agilent SurePrint Rat 60 K). We established two main
comparisons: FoxE1-silenced PCCl3 cells (siFoxE1 PCCl3) vs.
scrambled siRNA-treated PCCl3 cells (siScramble PCCl3) and
FoxE1-silenced PCCl3 cells vs. wild type PCCL3 cells (wt PCCl3).
This last condition was included to consistently analyse expression
array signals in basal cellular conditions. Each comparison was
performed using quadruplicates and dye swaps (Experimental
design shown in Fig. 1A).
Ten mg of total RNA for each condition were sent to the
Genomics Core Unit of the Spanish National Cancer Research
Centre (CNIO, Madrid) for RNA quality evaluation, amplifica-
tion, labelling and hybridization to Agilent SurePrint Rat 60 K
arrays according to the manufacturer’s protocols.
Signal quantification was carried out with Agilent Feature
Extraction Software 10.7 (Agilent Technologies, Palo Alto, CA),
using default analysis parameters for Agilent’s whole rat genome
60 K gene expression arrays. To normalize the data set, we
performed loess within-array normalization and quantiles be-
tween-array normalization. Differential expression analysis was
done using Bioconductor’s limma package (http://www.
bioconductor.org). At a later stage, we used the file ‘‘SurePrint
G3 Rat GE 8660 K Microarray’’ to obtain the annotations of the
rat genome from Agilent. Genes that showed adjusted p-values
,0.005 both in siFoxE1 vs. wild type and in siFoxE1 vs. siScramble
PCCl3 cells were considered differentially expressed. Functional
analysis of Gene Ontology (GO) terms was carried out using the
FatiGO tool and gene set enrichment analysis was performed
using FatiScan [27,28]. All microarray data can be downloaded
from the Gene Expression Omnibus (GEO; http://www.ncbi.nlm.
nih.gov/geo/) database under accession number GSE42497.
Experimental Validation of Expression Array Data
Technical validations of expression data were performed by
real-time quantitative PCR (qPCR) and western blots after
performing four independent experiments of FoxE1 silencing.
Total RNA was isolated from PCCl3 cells after silencing
following the standard TRIzol Reagent protocol (Invitrogen,
Carlsbad, CA). RNA was reverse transcribed with random primers
and quantitative PCR reactions were assembled in triplicate using
the SYBR Green PCR Kit (Kapa Biosystems, Woburn, MA)
following the manufacturer’s protocol. Expression level changes
were studied for 6 thyroid-specific genes (FoxE1, Tpo, Tg, Nis, Pax8
and Titf1) as well as for 12 putative FoxE1-regulated genes, using
beta-glucuronidase (Gus) for gene expression normalization (oligos
are shown in Table S1).
Total protein extracts were obtained by scraping the cells in
RIPA buffer (1% PBS, 0.5% (wt/vol) Nonidet, 0.1% (wt/vol)
sodium deoxycholate, 0.1% SDS). Protein extracts (30 mg) were
separated on 10% SDS-PAGE gels and immunodetected after
western blotting. FoxE1 antibody was from Biopat (Milan, Italy),
Actin and Cdh1 antibodies were from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA), and Nis and Duox2 antibodies were
generous gifts from Dr. N. Carrasco (Department of Cellular and
Molecular Physiology, Yale School of Medicine, New Haven, CT,
USA) [29] and Dr. C. Dupuy (Institut Gustave Roussy,Villejuif,
France) [30], respectively.
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Motif Search
We searched for FoxE1 binding sites in promoter regions (+/
21000 bp relative to the transcription start site) of genes
statistically significantly regulated by FoxE1 (p-values ,0.005).
We performed an automated search of genes containing both
the FoxE1 core binding site [59-ACAAA-39] and the NF1/CTF
binding motif [59-TTGG -39] localised between 5 to 30 bp from
the FoxE1 site, as previously described for FoxE1 binding
within the Tpo promoter [59-TTGG-(5–30)bp-ACAAA-39] [21].
FASTA promoter sequences of FoxE1-regulated genes, as well
as promoter sequences of their orthologous genes, were
extracted from the Ensembl database (http://www.ensembl.org).
ChIP and ReChIP Assays
Chromatin immunoprecipitation (ChIP) and sequential ChIP
(ReChIP) were performed using the Diagenode HighCell ChIP kit
following the manufacturer’s standard protocol. Cross-linked
PCCl3 chromatin was immunoprecipitated using polyclonal
antibodies against FoxE1 (Biopat, Milan, Italy) and NF1 (Abcam,
Cambridge, UK). Two independent ChIP experiments were
performed using two different batches of Biopat FoxE1 antibodies.
ReChIP was used to analyse simultaneous binding of FoxE1
and NF1/CTF proteins to a common DNA region. After a first
immunoprecipitation with FoxE1 antibody using the Diagenode
HighCell ChIP kit, samples were rinsed with RIPA buffer, and the
first antibody was stripped from the beads by incubating in 1%
SDS at 65uC for 15 minutes. Then a second round of
immunoprecipitation with NF1 antibody was performed using
Figure 1. Experimental design and FoxE1 protein levels after 48 hours of silencing. Panel A: Experimental design of expression array
experiments. Two comparisons were done: FoxE1-silenced PCCl3 cells (siFoxE1 PCCl3) vs. scrambled siRNA-treated PCCl3 cells (siScramble PCCl3), and
FoxE1-silenced PCCl3 cells vs. wild type PCCL3 cells (wt PCCl3). Each comparison was performed in quadruplicate and using dye swaps. Panel B:
Western Blot of extracts from control, siScramble and siFoxE1-treated cells from quadruplicate samples used for microarray analysis. Hybridizations
were done with anti-FoxE1 antibodies; anti-tubulin antibodies were used as loading controls.
doi:10.1371/journal.pone.0062849.g001
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the same Diagenode HighCell ChIP kit and following the
manufacturer’s standard protocol.
FoxE, NF1 and FoxE1/NF1 -immunoprecipitated and input
samples were analysed by real-time PCR using specific primers for
the analysed regions (see Table S2). The known FoxE1 targets Tpo
and Tg were used as positive IP controls whereas intron and
promoter regions of Gad1 (glutamate decarboxylase 1) and Afm
(afamin or alpha-albumin) were used as negative controls. qPCR
reactions were assembled in triplicate using the SYBR Green PCR
Kit (Kapa Biosystems, Woburn, MA), following the manufactur-
er’s protocol. The enrichment of target sequences in ChIP
material was calculated relative to the Afm and Gad1 negative
controls, and normalized to their relative amplification in the input
sample [31].
Transfection and Luciferase Assays
HeLa cells were plated at a density of 26105 cells/well in 6-well
tissue culture plates, 24 h before transfection. Transfections were
performed by calcium phosphate co-precipitation as described
previously [17]. The rat promoter pNIS 2.8-Luc, which contains
the NIS Upstream Enhancer (NUE) [32] was transiently
transfected alone (1.5 mg) or in combination with 1 mg of the
expression vectors CMV-FoxE1 (formerly CMV-TTF2) [3] or
RSV-CTF/NF1-C [33]. One hundred nanograms of the CMV-
Renilla vector were cotransfected to assess transfection efficiency.
After 48 h, cells were harvested, lysed, and analysed for Luciferase
and Renilla activities by the Dual-Luciferase reporter assay system
(Promega, Madison WI). The promoter activity in cells transfected
with expression vectors was determined as the ratio between
luciferase and Renilla activities, relative to the ratio obtained in
cells transfected with the corresponding control vectors. The
results shown are the average 6 SD of six different experiments
performed in triplicate. Statistical significance was determined by t
test analysis (two-tailed), and differences were considered signifi-
cant at p,0.05. Western blots were done where indicated to
determine the levels of expression of the transfected expression
vectors (data not shown).
Results
Gene Expression Profile of FoxE1-silenced Cells
In order to further investigate FoxE1 function and to identify
putative FoxE1 target genes in thyroid cells, we performed whole
genome microarray analysis in PCCl3 thyroid cells after knocking
down FoxE1. Silencing was performed for 48 h after transfection.
Data from four independent silencing experiments were analysed.
We obtained a FoxE1 silencing grade of more than 85% (Fig. 1B).
Statistically significant probes (p,0.005) from the siFoxE1 PCCl3
vs siScrambl PCCl3 comparison showed 74 differentially deregu-
lated probes, including 24 upregulated and 50 downregulated
probes. Comparison of siFoxE1 PCCl3 vs wt PCCl3 generated 211
differentially regulated probes, consisting of 99 upregulated and
112 downregulated probes (Table 1). Array results of both
comparisons are shown in datasets S1 and S2, respectively.
Statistically significant probes (p,0.005) from both comparisons
are shown in Table S3. Combination of significant results from
both comparisons showed 55 differentially deregulated genes, 17
of which were upregulated and 38 were downregulated (Tables 1
and 2). As expected, expression of previously known FoxE1 targets
(Tpo and Tg) was downregulated, in the absence of FoxE1, in both
comparisons.
Gene ontology (GO) analysis using FatiGO identified common
GO terms, including endoplasmic reticulum (ER) overload
response (GO:0006983), response to ER stress (GO:0034976),
cellular response to glucose starvation (GO:0042149), protein
folding (GO:0006457), heat shock protein binding, and oxidore-
ductase activity acting on sulfur group of donors, disulfide as
acceptor (GO:0016671).
Independent Validation of Genes Regulated by FoxE1
Silencing
We performed validations of microarray data using four
independent FoxE1 silencing experiments, 48 h after siRNA
transfection. First of all, we analysed expression levels of FoxE1,
in order to check and confirm its inhibition at the mRNA level.
We also checked the mRNA expression status of the FoxE1 target
genes Tpo and Tg, as well as mRNA levels of the classical, most
representative, thyroid genes: the thyroid iodide symporter gene,
Nis, and thyroid transcription factors Pax8 and Ttf1 (Fig. 2A).
Moreover, we validated 12 genes randomly chosen from the list
of putative FoxE1 targets, 5 of which were upregulated and 7 of
which were downregulated after FoxE1 silencing (Table 2). Genes
selected for this validation included: metallopeptidase Adamts9;
cadherin 1 (Cdh1), a cell-cell adhesion glycoprotein; Crip2, a
repressor of NF-kappaB; dual oxidase 2 (Duox2), a glycoprotein
located at the apical membrane of thyroid follicular cells; S100a4,
a calcium-binding protein; caspase 4 (Casp4), an apoptosis-related
cysteine peptidase; the cysteine-rich with GF-like domains protein
2, Creld2; dual specificity phosphatase 5 (Dusp5); transcription
factor Etv5; 70 kDa heat shock protein 5 (Hsp5a); steroid-thyroid
hormone-retinoid receptor Nr4a2; and transmembrane 4L six
family member 1, Tm4sf1.
After FoxE1 silencing, qRT-PCR analysis confirmed downreg-
ulation of FoxE1 as well as its previously described target genes
Tpo and Tg [17,18]. Interestingly, we also observed inhibition of
Nis, and its mRNA levels were decreased even more than Tg
mRNA levels (Fig. 2A). We confirmed the microarray data for
selected genes (Fig. 2B) with the only exception of the Crip2 gene,
whose qRT-PCR expression levels did not show differences after
FoxE1 silencing. All validation experiments were performed four
times, attesting to the robustness of the results.
We confirmed that mRNA levels of Adamts9, Cdh1, Duox2 and
S100a4 were upregulated, and those of Casp4, Creld2, Dusp5, Etv5,
Hsp5a, Nr4a2 and Tm4sf1 were downregulated when FoxE1 was
silenced in thyroid cells.
The protein expression of FoxE1 was analysed in order to check
and confirm its inhibition at the protein level. We then checked
protein levels of three FoxE1 putative target genes, Nis, Duox2 and
Cdh1 (Figs 2C and 2D). After FoxE1 silencing, Duox2 protein levels
did not change, but we confirmed inhibition of Nis expression and
overexpression of Cdh1, at protein level.
Table 1. Summary of FoxE1 microarray results in PCCl3 cells.
siFoxE1 vs
siScrambl siFoxE1 vs WT Common
p-value,0.005 Probes Genes Probes Genes Genes
Total 74 64 211 183 55
Upregulated 24 24 99 87 17
Downregulated 50 40 112 96 38
Number of statistically significant probes and genes (p,0.005) after Foxe1
silencing; results are shown for each type of comparison performed, as well as
for the combined analysis.
doi:10.1371/journal.pone.0062849.t001
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Identification and Functional Analysis of Direct FoxE1
Targets
With the aim of investigating new direct FoxE1 targets, first we
searched for the specific FoxE1 core binding sequence, AAACA,
in promoter regions of putative FoxE1 regulated genes (+/
21000 pb). However, AAACA is a short sequence that can be
easily found at random in the genome. We therefore performed an
automatic search in the promoter sequences for FoxE1 binding
sites in close proximity (5–30 bp) to the NF1/CTF binding motif,
[59-TTGG-(5–30)bp-ACAAA-39], as previously described for
FoxE1 binding to the Tpo promoter [21] and for other forkhead
family members [34].
FoxE1-NF1/CTF binding sequences were present in promoter
regions of 26 out of 55 differentially FoxE1-regulated genes.
Results are summarized in Table 3. Considering their previously
described function in thyroid biology, we selected three of these
genes: Duox2, Cdh1 and Nr4a2 for performing ChIP in vivo analysis
of FoxE1 binding to their promoters.
We also wanted to study in more detail the role of FoxE1 in Nis
regulation (Fig. 2A). As we detected that Nis mRNA levels were
even more strongly reduced than Tg mRNA levels, we tried to find
FoxE1-NF1/CTF binding sequences in both the Nis proximal
promoter (+/21000 pb) and in the Nis upstream enhancer
element (NUE ) localised between –2495 and –2264 bp [35]. A
FoxE1-NF1/CTF binding sequence was detected in the NUE,
close to a previously described Pax8 binding sequence [35]
(Fig. 3A), but not in the proximal Nis promoter.
In order to analyse in vivo FoxE1 binding to Duox2, Cdh1, Nr4a2
and Nis promoter sequences, we performed chromatin immuno-
precipitation (ChIP) using a polyclonal antibody against FoxE1.
We analysed immunoprecipitated DNA of two independent
experiments using qPCR. Results of IP ratios normalized to the
Afm negative control are shown in Fig. 4. The same results were
obtained when we used Gad1 as a negative control (data not
shown). Previously described FoxE1 binding sequences in the Tg
and Tpo promoters were used as positive controls.
The FoxE1 antibody precipitated FoxE1 target sequences in the
Tg and Tpo promoters with relative immunoprecipitation (IP)
Figure 2. Experimental validation of microarray results by qRT-PCR and western blotting. Relative expression assessed by means of qRT-
PCR of 6 thyroid-specific genes (panel A) and 12 additional genes differentially down- and upregulated in FoxE1-silenced PCCl3 cells (panel B). As
FoxE1-dependent positive controls, we evaluated Tpo and Tg mRNA expression levels. Relative gene expression in siFoxE1 samples was calculated
using the corresponding siScrambl samples as a reference ( = 1). Results are mean 6 SEM of four independent experiments. Total protein extracts
were prepared and submitted to western blot analysis to assess the protein levels of FoxE1 and Nis (panel C), and of Cdh1 and Duox2 (panel D). Actin
was used as loading control. Representative western blot assays of four independent experiments are shown.
doi:10.1371/journal.pone.0062849.g002
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Table 2. Description of statistically genes significantly (p,0.005) regulated by FoxE1.
Gene Status
Selected for
validation Description
Ahcy Downreg. No Catalyzes the reversible hydrolysis of S-adenosylhomocysteine (AdoHcy) to adenosine (Ado) and L-homocysteine (Hcy).
Amigo3 Downreg. No Adhesion molecule with Ig-like domain 3.
Ankrd37 Downreg. No Ankyrin repeat domain 37, ANKRD37 is a novel HIF-1-target gene.
Atmin Downreg. No ATM interactor, an essential cofactor for checkpoint kinase ATM, ATMIN.
Bet1 Downreg. No This gene encodes a golgi-associated membrane protein that participates in vesicular transport from the endoplasmic
reticulum (ER) to the Golgi complex.
Casp4 Downreg. Yes Caspase 4, apoptosis-related cysteine peptidase; sequential activation of caspases plays a central role in the execution
phase of cell apoptosis.
Coq10b Downreg. No Coenzyme Q10 homolog B (S. cerevisiae).
Creld2 Downreg. Yes Cysteine-rich with EGF-like domains 2; the CRELD family has widely diverse biological roles in both developmental
events and subsequent cell function.
Ctgf Downreg. No The encoded protein plays a role in chondrocyte proliferation and differentiation, cell adhesion in many cell types, and
is related to platelet-derived growth factor.
Ddit3 Downreg. No DNA-damage-inducible transcript 3; the protein is implicated in adipogenesis and erythropoiesis, is activated by
endoplasmic reticulum stress, and promotes apoptosis.
Derl3 Downreg. No Der1-like domain family, member 3: this protein appears to be involved in the degradation of misfolded glycoproteins
in the ER.
Dnajb11 Downreg. No DNAJB11 belongs to the evolutionarily conserved DNAJ/HSP40 family of proteins, which regulate molecular chaperone
activity by stimulating ATPase activity.
Dnajb9 Downreg. No DnaJ (Hsp40) homolog, subfamily B, member 9; this protein is induced by endoplasmic reticulum stress and plays a role
in protecting stressed cells from apoptosis.
Dnajc3 Downreg. No It is a member of the tetratricopeptide repeat family of proteins and acts as an inhibitor of the interferon-induced,
dsRNA-activated protein kinase (PKR).
Dusp5 Downreg. Yes It negatively regulates members of the mitogen-activated protein (MAP) kinase superfamily (MAPK/ERK, SAPK/JNK,
p38), which are associated with cellular proliferation and differentiation.
Engase Downreg. No Endo-beta-N-acetylglucosaminidase, (ENGase; EC 3.2.1.96) is involved in the processing of free oligosaccharides in the
cytosol.
Ero1lb Downreg. No ERO1-like beta (S. cerevisiae), endoplasmic oxidoreductin-1-like protein B.
Etv5 Downreg. Yes Ets variant gene 5; ETV5 belongs to the PEA3 subfamily of Ets transcription factors.
Ggct Downreg. No Gamma-glutamylcyclotransferase; the encoded protein may also play a role in cell proliferation, and the expression of
this gene is a potential marker for cancer.
Gmppb Downreg. No GDP-mannose pyrophosphorylase B; catalyzes the conversion of mannose-1-phosphate and GTP to GDP-mannose, a
reaction involved in the production of N-linked oligosaccharides.
Hsp90b1 Downreg. No Heat shock protein 90 kDa beta (Grp94), member 1; HSP90 proteins have key roles in signal transduction, protein
folding, protein degradation, and morphologic evolution.
Hspa5 Downreg. Yes Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa); as this protein interacts with many ER proteins, it may
play a key role in monitoring protein transport through the cell.
Hyou1 Downreg. No Hypoxia upregulated 1; the protein encoded by this gene belongs to the heat shock protein 70 family. This gene uses
alternative transcription start sites.
Igf2bp2 Downreg. No Insulin-like growth factor 2 mRNA binding protein 2; it functions by binding to the 59 UTR of the insulin-like growth
factor 2 (IGF2) mRNA and regulating IGF2 translation.
Il23a Downreg. No Interleukin 23, alpha subunit p19; both IL23 and IL12 can activate the transcription activator STAT4, and stimulate the
production of interferon-gamma (IFNG).
LOC365444 Downreg. No Similar to CGI-09 protein.
Manf Downreg. No Mesencephalic astrocyte-derived neurotrophic factor. Reducing expression of this gene increases susceptibility to ER
stress-induced death and promotes cell proliferation.
Mfsd2 Downreg. No Major facilitator superfamily domain containing 2A. Mfsd2a plays a role in adaptive thermogenesis, it is a lung tumor
suppressor gene that regulates cell cycle progression and matrix attachment.
Nr4a2 Downreg. Yes Nuclear receptor subfamily 4, group A, member 2; this gene encodes a member of the steroid-thyroid hormone-
retinoid receptor superfamily. The encoded protein may act as a transcription factor.
Nupr1 Downreg. No Nuclear protein, transcriptional regulator 1. It was originally identified as p8, a member of the family of HMG-I/Y
transcription factors induced in response to various cellular stressors.
Pdia4 Downreg. No Protein disulfide isomerase family A, member 4.
Riok3 Downreg. No RIO kinase 3 (yeast); the specific function of this gene has not yet been determined.
Sdf2l1 Downreg. No Stromal cell-derived factor 2-like 1, a component of the endoplasmic reticulum chaperone complex.
Novel FoxE1 Targets in Thyroid Cells
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ratios of 22.8 and 3.6, respectively. We found binding of FoxE1 to
chromatin regions containing the Nis upstream enhancer element
(relative IP ratio: 12.6). We also observed positive FoxE1 binding
to two DNA sites located in the Duox2 gene; one in the promoter
sequence at 2351 bp (relative IP ratio: 28.1) and the other in the
third exon at +696 bp (relative IP ratio: 9.3) (Figs 3 and 4). We did
not detect direct FoxE1 interactions with either Cdh1 or Nr4a2.
In order to better understand whether FoxE1 and NF1/CTF
are bound together on the Nis and Duox2 promoter regions, we
performed ChIP assays using a polyclonal antibody against NF1.
Next, we also performed ReChIP experiments with FoxE and NF1
antibodies. We quantified immunoprecipitated DNA regions using
qPCR. The previously described FoxE1 binding sequence in the
Tg promoter was used as positive control.
In our experimental conditions, we did not observe in vivo NF1/
CTF binding to either of the two putative FoxE1 binding
sequences in Duox2 (data not shown). Nevertheless, we detected
positive binding of NF1/CTF to the NUE. Moreover, we observed
simultaneous FoxE1 and NF1/CTF binding to the NUE region.
Results of IP ratios normalised to the Afm negative control are
shown in Fig. 5A. Similar results were obtained when Gad1 was
used as a negative control (data not shown).
As we wanted to study in depth the role of FoxE1 and NF1/
CTF in Nis regulation, we cotransfected HeLa cells with FoxE1
and NF1/CTF expression vectors, together with a luciferase
expression vector containing the NUE. Forty-eight hours later,
cells were lysed and luciferase levels were measured. The results
showed a significant 2-fold increase in the activity of NUE when
FoxE1 or NF1/CTF were expressed individually in HeLa cells;
thus, the effect was additive when both transcription factors were
transfected together (Fig. 5B).
In summary, we present the first description of specific in vivo
FoxE1 binding to regulatory regions of two relevant thyroid genes,
Nis and Duox2. These FoxE1 core binding sequences are located
close to a NF1/CTF transcription factor binding site. Moreover,
we demonstrate that FoxE1 and NF1/CTF are simultaneously
bound to the Nis upstream enhancer and that they cooperate in
the regulation of NIS-promoter activity.
Table 2. Cont.
Gene Status
Selected for
validation Description
Sec23b Downreg. No Sec23 homolog B (S. cerevisiae). The protein encoded by this gene is a member of the SEC23 subfamily of the SEC23/
SEC24 family, which is involved in vesicle trafficking
Sel1l Downreg. No Sel-1 suppressor of lin-12-like is part of a protein complex required for the retrotranslocation or dislocation of misfolded
proteins.
Tm4sf1 Downreg. Yes Transmembrane 4 L six family member 1. The proteins mediate signal transduction events that play a role in the
regulation of cell development, activation, growth and motility.
Tmem66 Downreg. No Transmembrane protein 66.
Zfand2a Downreg. No Zinc finger, AN1-type domain 2A.
Adamts9 Upreg. Yes ADAM metallopeptidase with thrombospondin type 1 motif, 9. Members of the ADAMTS family have been implicated
in the cleavage of proteoglycans, organ development, and angiogenesis.
Bcam Upreg. No Basal cell adhesion molecule, member of the immunoglobulin superfamily and a receptor for the extracellular matrix
protein laminin.
Cdh1 Upreg. Yes Cadherin 1; the encoded protein is a calcium dependent cell-cell adhesion glycoprotein.
Crip2 Upreg. Yes Cysteine-rich intestinal protein 2 (CRIP2); acts as a repressor of NF-kappaB-mediated proangiogenic cytokine
transcription to suppress tumorigenesis and angiogenesis.
Duox2 Upreg. Yes It is a glycoprotein and a member of the NADPH oxidase family; the synthesis of thyroid hormone is catalyzed by a
protein complex located at the apical membrane of thyroid follicular cells.
Dynlrb2 Upreg. No Dynein light chain roadblock-type 2
Elovl2 Upreg. No ELOVL fatty acid elongase 2.
Fgf18 Upreg. No Fibroblast growth factor 18; involved in a variety of biological processes, including embryonic development, cell
growth, morphogenesis, tissue repair, tumor growth, and invasion.
Folr1 Upreg. No This gene product is a secreted protein that either anchors to membranes via a glycosyl-phosphatidylinositol linkage or
exists in a soluble form.
Krt20 Upreg. No Keratin 20; the keratins are intermediate filament proteins responsible for the structural integrity of epithelial cells and
are subdivided into cytokeratins and hair keratins.
Prima1 Upreg. No Proline-rich membrane anchor 1; the product of this gene functions to organize acetylcholinesterase (AChE) into
tetramers, and to anchor AChE at neural cell membranes.
Prss8 Upreg. No Protease, serine, 8; this gene encodes a trypsinogen, which is a member of the trypsin family of serine proteases.
Ril Upreg. No Reversion-induced LIM gene, binds alpha-actinin; may regulate actin stress fiber turnover.
RT1-Da Upreg. No MHC class II RT1D alpha chain antigen.
S100a4 Upreg. Yes S100 calcium binding protein A4; S100 proteins are involved in the regulation of a number of cellular processes such as
cell cycle progression and differentiation.
Slit1 Upreg. No Slit homolog 1; the genes encoding Slits and their Robo receptors are silenced in many types of cancer, including
breast, suggesting a role for this signaling pathway in suppressing tumorigenesis.
Tmem140 Upreg. No Transmembrane protein 140.
doi:10.1371/journal.pone.0062849.t002
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Discussion
FoxE1 is a forkhead transcription factor essential for thyroid
differentiation and function. In humans, FOXE1 mutations cause
the Bamforth–Lazarus syndrome (OMIM 241850) [9,10]. In spite
of this, FoxE1 expression levels seem to be unaltered in human
tumours. As reflected in the Gene Expression Omnibus database,
FOXE1 variations have been associated with susceptibility to
several types of cancer [11,12,13], including papillary thyroid
cancer [14,15,16]. FoxE1 recognizes and binds to the Tg and Tpo
promoters. However, little is known about other downstream
targets of FoxE1 that could explain the phenotypes observed in
humans carrying variations in FoxE1. Only two studies reporting
novel genes regulated by FoxE1 have been published until now
[22,23], but both were done in a heterologous system overex-
pressing FoxE1. Our goal was to find new potential downstream
mediators of FoxE1 function in vivo, but importantly, instead of a
heterologous system we used a thyroid cell line. Results obtained
by performing a genome-wide approach followed by chromatin
immunoprecipitation analysis, led us to the identification of direct
FoxE1 target genes in thyroid cells.
In this study, we found 54 putative novel FoxE1 target genes.
We obtained a very restrictive list of significantly regulated genes,
based on overlapping expression array data of two comparisons.
This restrictive list did not allow us to obtain relevant information
about main pathways affected by FoxE1 action. We identified and
validated eleven genes regulated by FoxE1; four of them (Adamts9,
Cdh1, Duox2 and S100a4) showed an increased expression, whereas
the remaining seven genes (Casp4, Creld2, Dusp5, Etv5, Hsp5a,
Nr4a2 and Tm4sf1) showed decreased mRNA levels when FoxE1 is
silenced. Moreover, we have not ruled out that the other 43
statistically significant genes are true FoxE1 targets, and in future
studies we will take advantage of these additional array results.
In order to identify genes directly regulated by FoxE1, we
performed an in silico search of the FoxE1 binding motif in the
promoter regions of 54 statistically significant genes. As the FoxE1
core binding sequence is very short, only five nucleotides, we were
forced to perform a more restrictive search including the NF1/
CTF binding sequence, as previously described for the Tpo
promoter [21] and for other forkhead factors in the serum albumin
gene promoter [34]. It has been proposed that the conserved
interaction between NF1/CTF and forkhead proteins could reflect
a general mechanism of action of both families of transcription
factors. The NF1/CTF-binding site is masked inside the
nucleosomal structure; binding of forkhead proteins to their
cognate sites opens this structure and makes the NF1/CTF site
accessible to exert its transactivation effect. The ability of the
forkhead domain to induce DNA bending [36] would promote
contact with NF1/CTF factors. It has been hypothesised that this
Figure 3. Putative FoxE1-NF1/CTF binding sites in the Duox2 gene and in the NUE. Chromosomal location of putative FoxE1 and NF1/CTF
binding motifs in the Nis upstream enhancer (panel A) and the Duox2 gene (panel B). Oligos used and exons are represented in italics.
doi:10.1371/journal.pone.0062849.g003
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interaction may play an important role in cell type-specific
transcription and might be a widespread phenomenon [21].
Duox2 codes for the enzyme that catalyzes H2O2 production in
the thyroid gland [37,38,39]. Duox2 expression is found in the
thyrocyte more abundantly than in several other cell types [40]. In
humans, mutations in the corresponding gene are associated with
congenital hypothyroidism [41,42]. Duox2 regulation by the
classical thyroid transcription factors Pax8 and Ttf1 has been
studied in depth, however, two main studies reported controversial
results [40,43]. Nevertheless, until now there were no indications
in the literature of a role of FoxE1 in Duox2 regulation.
In the present work we demonstrate that FoxE1 interacts in vivo
with two DNA regions located in Duox2. We observed FoxE1
binding to the promoter region at 2351 bp and to a second
regulatory region located in exon 3 at +696 bp (Figs 3 and 4).
However Duox2 did not seem to be regulated by FoxE1 at the
protein level, indicating the involvement of strong post-transcrip-
tional regulatory mechanisms. Since Duox2 mRNA expression
increases when FoxE1 is silenced and since FoxE1 binds directly to
two Duox2 regulatory regions, we can hypothesise that FoxE1 is
acting as a transcriptional repressor of Duox2.
The repressor function of FoxE1 has been previously reported.
FoxE1 represses the transcriptional activity of Ttf1 and Pax8
during thyroid development through its C-terminal region, which
contains an alanine-rich domain [3,19]. FoxE1 also inhibits
estrogen receptor a transactivation through this domain [44]. In
line with our hypothesis, a direct repression function that may
require both target DNA binding and dimerization domains [45]
has been demonstrated for other forkhead family members such as
FoxP.
Figure 4. ChIP experiments for FoxE1 binding to selected
genes. qPCR analysis of chromatin immunoprecipitation performed on
PCCl3 cells with FoxE1 antibody. The enrichment of target sequences
was calculated as the IP ratio (arbitrary units) relative to the negative
control Afm, and normalized to their relative amplification in the input
sample. Sequences from the Tg and Tpo promoters were used as
positive controls. Two regulatory regions were analysed in the Duox2
promoter (called Duox2-1 and Duox2-2). Results are mean 6 SEM of
two independent experiments, each performed in triplicate.
doi:10.1371/journal.pone.0062849.g004
Figure 5. FoxE1 and NF1/CTF binding to and transcriptional activation of the NUE. A ReChIP assay was used to analyse simultaneous
binding of FoxE1 and NF1/CTF proteins to the NUE (panel A). qPCR was done to analyse chromatin immunoprecipitates of PCCl3 cells using FoxE1
and NF1 antibodies. The enrichment of target sequences was calculated as the IP ratio (arbitrary units) relative to the negative control Afm, and
normalized to their relative amplification in the input sample. A sequence from the Tg promoter was used as positive control. HeLa cells were
transfected with 1 mg of a FoxE1 or NF1/CTF expression vector or the empty vector, and 1.5 mg and 0.1 mg of pNIS 2.8-Luc and CMV-Renilla constructs
respectively (panel B). Forty-eight hours after transfection, cells were collected for the measurement of luciferase and renilla levels. Results are shown
as the mean6SD of the luciferase levels relative to the non-regulated renilla levels of six independent experiments. (*): p,0.05; (**): p,0.01; (***):
p,0.001; two tailed t-test.
doi:10.1371/journal.pone.0062849.g005
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FoxE1 binding domains in Duox2 regulatory regions are
localised at 26 and 27 bp from the NF1/CTF binding motif
(Table 3). Nevertheless, in our experimental conditions, we were
not able to detect direct in vivo binding of NF1/CTF to either of
the two FoxE1 core sequences in Duox2. Thus, the exact FoxE1-
mediated repression mechanism of Duox2 expression remains to be
elucidated.
Cdh1 belongs to a superfamily of glycoproteins that mediate
calcium-dependent cell-cell adhesion. Cdh1 is highly expressed in
the normal thyroid gland and its expression leads to aggregation of
thyrocytes [46]. Moreover, thyroid-stimulating hormone (TSH) in
dog and human thyroid cell cultures regulates Cdh1 transcription
[47], suggesting a relationship between Cdh1 expression and
thyroid differentiation. FoxE1 expression itself is under TSH
control [48]. Therefore it seems plausible that TSH, via FoxE1
and other players, might regulate expression levels of Cdh1. In
fact, we observed an increased Cdh1 mRNA and protein
expression when FoxE1 was silenced; nevertheless, we were not
able to detect a direct interaction between FoxE1 and Cdh1.
Nr4a2 is a transcription factor that belongs to the steroid-
thyroid hormone-retinoid receptor superfamily. In addition,
Nr4a2 is a member of the NR4A subfamily of nuclear orphan
receptors that function as ligand-independent early response genes
involved in proliferation, apoptosis, and inflammation [49]. Nr4a2
cooperates with another member of the forkhead protein family,
FoxA2, during dopamine neuron differentiation [50] and Nr4a2
overexpression enhances migration of mesenchymal stromal cells
[49]. Our data reveals a downregulation of Nr4a2 expression when
FoxE1 is absent, but, in our experiments, FoxE1 did not directly
bind to its promoter.
Further studies will be done to analyse in depth the apparently
indirect regulation by FoxE1 of Nr4a2 and Cdh1 and its implication
in cellular migration and/or thyroid differentiation.
Surprisingly, in the absence of FoxE, we observed both reduced
Nis mRNA levels and reduced Nis protein levels (Fig. 2A and C).
We found one FoxE1 core binding sequence and three NF1/CTF
motifs in the NUE (Fig. 3A). NUE stimulates transcription in a
thyroid-specific, cAMP-dependent manner and involves the most
relevant aspect of Nis regulation. NUE contains Ttf1 binding sites
that have no known effect on Nis transcription, Pax8 binding sites,
and a degenerate cAMP responsive element sequence [35]. In
their original study, Ohno et al. performed DNase I footprinting
analysis of the NUE, but no footprints were detected when FoxE1
was used [35]. The first and foremost possibility that might explain
the apparent discrepancy with our results is that Ohno et al. did
in vitro experiments. In a later study, Li et al. suggested that FoxE1
participates in a human NIS repressor complex, together with
PARP-1 [51]. Our study clearly demonstrates a direct in vivo
interaction of FoxE1 with the NUE and a modification of Nis
transcriptional activity in the absence of FoxE1. In addition, we
observed direct NF1/CTF binding to the NUE, and we also
demonstrated that FoxE1 and NF1/CTF are bound together on
the NUE region. Binding of both transcription factors together
resulted in an increased transcriptional activity of the NUE,
confirming their cooperation in Nis regulation (Fig. 5).
Our work emphasizes the idea of a cross-talk of thyroid
transcription factors during the process of transcriptional regula-
tion, controlling key cellular processes for thyrocyte biology, with
different roles of several players of this complex regulatory system
that are still emerging.
On the one hand, a master thyroid gene, Nis, contains in its
NUE binding sequences for Pax8, Ttf-1 and FoxE1-NF1/CTF
that appear to be linked in a complex network of reciprocal
regulatory interactions. On the other hand, another of the best
candidate genes in our genome-wide study is the thyroid gene
Duox2; thus, evidence is accumulating regarding the existence of a
regulatory network in the thyroid involving FoxE1.
Finally, our study points out the importance of cooperating
transcription factors and the usefulness of previously used tools,
especially the in silico search of transcription factor binding
sequences. Core sequences are necessary but not sufficient, and
flanking sequences determine transcription factor binding speci-
ficity [23,48]. The use of the FoxE1-NF1/CTF binding motif [21]
led us to obtain a workable restrictive list of potential direct FoxE1
targets. Moreover, this opens a window to further investigating the
cooperative function of FoxE1 and NF1/CTF in transcriptional
regulation of our candidate genes, as we demonstrated to occur for
Nis expression.
In search of potential downstream mediators of FoxE1 function,
we identified Nis and Duox2 as novel direct FoxE1 target genes. To
our knowledge, this is the first evidence regarding the implication
of Nis and Duox2 in executing the transcriptional programme
triggered by FoxE1. Both are pivotal proteins required for thyroid
gland differentiation and function.
Although mainly acting as a regulator of the expression of the
thyroid genes Tg, Tpo, Nis and Duox2, FoxE1 may also act in
thyroid cells as a transcriptional regulator of many other candidate
genes, some of which are suggested in the present study.
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